Dr. Sujitha Subash Padma Jeya | Hamad Bin Khalifa University
Hamad Bin Khalifa University


Dr. Sujitha Subash Padma Jeya

Dr. Sujitha Subash Padma Jeya (PhD)

Postdoctoral Fellow
Translational Oncology Research Center
Qatar Biomedical Research Institute


Dr. Sujitha Subash Padma Jeya was awarded with the PhD in Biotechnology from VIT University, Vellore, Tamil Nadu, India. In her PhD project she investigated the genetic variants associated with Schizophrenia, with special reference to gene polymorphisms in the Serotoninergic system, ESR1 and DNA repair gene (XRCC1) in Tamil population (South India). This study was supported by the Department of Biotechnology (DBT) Ministry of Science & Technology, Government of India. 

In 2018, Dr. Sujitha joined the Human Genetics Department, Precision Medicine Program, Sidra Medicine, Qatar, as a Research Specialist. Over there, she worked on several research projects funded by Qatar National Research Fund (QNRF). She was involved in validating the susceptible variants discovered through 'Whole Genome Sequencing in the Mendelian and Autism' disease subjects. But her special focus was finding the molecular biomarker for Diabetic retinopathy in Qatar's Population using multi-OMICS (circulating miRNA profiling, mRNA expression profiling, methylation profiling, proteomics profiling) approach. As part of the Diabetes Precision Medicine Program, she validated the hub of genes orchestrating the podocytes functions, which were discovered through the Geodata set analysis (retrospective analysis). She has demonstrated the involvement of susceptible transcription factors in pronephros development in Zebrafish hyperglycemic models. She also worked in the 'Qatar Genome Project' assessing the impact of amylase genes Copy Number Variation (Structural Variants) on adiposity in Qatar's Population.

Dr. Sujitha, joined Dr. Fares Al-Ejeh team as a Post-Doctoral Researcher in 2022, and is currently involved in finding clinically actionable potential biomarkers in Qatar's population for Cancer Precision Medicine.


Research Interests

Dr. Sujitha is interested in unraveling the molecular underpinnings that orchestrate the non-responding groups in multiple stages of Breast cancer (Stage II to Stage IV). She is involved in developing in vitro 3-D multicellular tissue construct or cellular model mimicking the disease stage and further to predict the treatment strategy for those specific groups for a better prognosis and to lead a better life. 


Research Specialist

Sidra Medicine, Qatar

2018 - 2022


PhD Vellore

Institute of Technology, Tamil Nadu, India


Selected Publications

  • Niccolo’ Rossi, Elbay Aliyev, Alessia Visconti, Ammira SA Akil, Najeeb Syed, Waleed Aamer, Sujitha S Padmajeya, Mario Falchi, Khalid A Fakhro

    Ethnic-specific association of amylase gene copy number with adiposity traits in a large Middle Eastern biobank; NPJ genomic medicine 6 (1), 1-9.

  • Ammira-Sarah AL-Shabeeb Akil, Laila F Jerman, Esraa Yassin, Sujitha S Padmajeya, Alya Al-Kurbi, Khalid A Fakhro

    Reading between the (Genetic) lines: How epigenetics is unlocking novel therapies for type 1 diabetes; Cells 9 (11), 2403.

  • W Aamer, A Almaraghi, A Al-Kurbi, S Padmajeya, A Al-Shakaki, A Robay, M Kamal, A Akil, T Ben Omran, KA Fakhro

    The Qatari Mendelian program-A premium resource for gene discovery and data sharing for rare diseases from the greater Middle East; EUROPEAN JOURNAL OF HUMAN GENETICS 28 (SUPPL 1), 470-470.

  • SP Sujitha, D Thirumal Kumar, C George Priya Doss, K Aavula, R Ramesh, S Lakshmanan, S Gunasekaran, G Anilkumar

    DNA Repair Gene (XRCC1) Polymorphism (Arg399Gln) Associated with Schizophrenia in South Indian Population: A Genotypic and Molecular Dynamics Study; PLoS One 11 (1), e0147348.

  • Subash Padmajeya Sujitha, Asha Nair, Moinak Banerjee, Srinivasan Lakshmanan, Sampth Harshavaradhan, Soosiah Gunasekaran, Anilkumar Gopinathan

    5-Hydroxytryptamine (serotonin) 2A receptor gene polymorphism is associated with schizophrenia; The Indian journal of medical research 140 (6), 736.